Truist Financial Remains a Buy on Taysha Gene Therapies (TSHA)

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Taysha Gene Therapies. The company’s shares closed yesterday at $5.00.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Lee covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Corcept Therapeutics, and Praxis Precision Medicines. According to TipRanks, Lee has an average return of 28.0% and a 56.05% success rate on recommended stocks.

In addition to Truist Financial, Taysha Gene Therapies also received a Buy from Canaccord Genuity’s Whitney Ijem in a report issued today. However, on October 3, TR | OpenAI – 4o reiterated a Hold rating on Taysha Gene Therapies (NASDAQ: TSHA).

TSHA market cap is currently $1.38B and has a P/E ratio of -14.00.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TSHA in relation to earlier this year. Most recently, in August 2025, Kamran Alam, the CFO of TSHA sold 54,491.00 shares for a total of $155,299.35.